A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL
Tools
Tools
Symanowski, James, Vogelzang, Nicholas, Zawel, Leigh, Atadja, Peter, Pass, Harvey and Sharma, Sunil (2009) A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer, 4 (2). pp. 149-160. ISSN 1556-1380
Abstract
PURPOSE: Tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a member of tumor necrosis factor family and it is important for ligand induced apoptosis in tumor cells. TRAIL has been shown to be synergistic with a variety of chemotherapies and targeted agents. In the study, a combination of TRAIL and a histone deacetylase inhibitor LBH589 was studied in mesothelioma cell lines. EXPERIMENTAL DESIGN: Five mesothelioma cell lines and two normal cell lines were tested for cell growth inhibition and apoptosis using high-throughput assays in the presence of LBH589, TRAIL and a combination of the two. Caspase induction was studied and levels of X-linked inhibitor of apoptosis (XIAP) were tested using Western blotting. A combination of a direct inhibitor of XIAP was also tested in combination with TRAIL. RESULTS: In mesothelioma cell lines, a combination of LBH589 and TRAIL markedly increased cell growth inhibition and apoptosis when compared with the effect on normal cell lines. LBH589 and TRAIL appeared to induce higher levels of caspase 3 and 7 and this appeared to be closely related to ability of LBH589 to degrade XIAP. In addition, a direct inhibitor of XIAP was also sensitized cells to TRAIL apoptosis, providing an indirect confirmation for XIAP degradation as a possible mechanism of synergy. CONCLUSIONS: In mesothelioma cell lines, LBH589 increases the sensitivity to TRAIL. In addition, at least partly, the mechanism of this induction of TRAIL sensitivity is due to LBH589 related degradation of XIAP. These results provide initial evidence for testing this combination in clinical trials.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | Author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used |
| Keywords: | Mesothelioma; Histone deacetylase inhibitors; apoptosis; Tumor necrosis factor-alpha-related apoptosis-inducing ligand |
| Related URLs: | |
| Date Deposited: | 22 Feb 2010 11:50 |
| Last Modified: | 31 Jan 2013 00:51 |
| URI: | https://oak.novartis.com/id/eprint/1693 |